The global wound closure market is worth in excess of €6Bn per annum. The Relialoc device aims to disrupt the conventional surgical wound closure market (sutures & staples) which is estimated to be approx €4Bn per annum.
Theatre time is an expensive commodity, estimated to cost €50 / $80 per minute. Surgical wound closure on average takes 1 minute per 1.5cm of wound closed. Relialoc aims to decrease the time taken for skin closure by 80% thus increasing case throughput in the operating theatre. The product aims to diminish post operative infection and wound discharges which can lengthen a patient's hospital stay by optimizing soft tissue wound closure.